Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
$8.72
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.72
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$8.04 - $23.60
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$242.49M
Enterprise Value$128.45M
Total Cash (Recent Filing)$196.47M
Total Debt (Recent Filing)$22.93M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 10, 2025EPS Estimate
-0.9Last Dividend Ex-Date
Jan 08, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding27,154,530
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.90
Price to Sales (P/S)3.31
P/FCF Ratio-7.59
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$25.40Price Target Upside191.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityARCT ended 2Q25 with $253.4M in cash, ensuring financial stability.
Market OpportunityCystic fibrosis is modeled as a greater than $1 billion sales opportunity for Arcturus, indicating significant revenue potential.
MRNA Platform PotentialThere is value in the LUNAR LNP platform and the exclusive mRNA purification technology to drive future value in other indications that might benefit from mRNA therapy.
Bears Say
Clinical Trial ChallengesThe cystic fibrosis (CF) program is not considered worth progressing towards later stage clinical trials due to lack of efficacy signals.
Efficacy ConcernsThe data failed to demonstrate a meaningful improvement in FEV1/ppFEV1, had a high level of variability between patients, and had a lack of concordance between FEV1 and mucus plug/volume reductions.
Stock ValuationThe value from the CF and OTC deficiency programs has been removed from the valuation, reducing the price target to $12 and downgrading the stock to Neutral.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $8.04 and its highest was $23.59 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $242.49M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is tomorrow.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.892 by $0.552.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,154,530 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.892. Following the earnings report the stock price went up 30.729%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
Arcturus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.40 (191.28% Upside)
$25.40 (191.28% Upside)
Hedge Fund Trend
Decreased
By 293.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-24.57%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in key therapeutic programs, financial stability, and advancements in regulatory processes. Despite the decrease in revenue, the company's strategic restructuring and strong financial position, along with promising clinical trial results, contribute to an optimistic future outlook.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$25.40
▲(191.28% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.42% Insiders
30.49% Mutual Funds
31.09% Other Institutional Investors
10.14% Public Companies and Individual Investors